The study was performed in the UK by Covance, one of the worlds leading CRO's, and proved AMAP102 to be safe and tolerable and with pharmacokinetic properties encouraging continued development.

AnaMar is now preparing for the Phase II study aiming to generate clinical Proof of Concept in patients with Rheumatoid Arthritis.

The Phase II study is planned to be initiated in the second half of 2010.